Randomized Phase III Trial of Bortezomib; LENalidomide and Dexamethasone (VRd) Versus Carfilzomib; Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)